Frequently Asked Questions About Lamisil (Terbinafine)
1.What is Lamisil (Terbinafine)?
2.How Does Lamisil Work?
3.Which Fungal Infections Does Lamisil Address?
4.Is Lamisil Effective for Nail Fungus?
5.How Long Does it Take for Lamisil to Show Results?
6.Can Lamisil Be Used for Scalp Ringworm?
7.In What Forms is Lamisil Available?
8.Can Lamisil Tablets be Crushed for Easier Administration?
9.What Should I Do If I Miss a Dose of Lamisil?
10.Does Lamisil Have Side Effects?
11.Is Lamisil Safe for Children?
12.Can Lamisil Interact with Other Medications?
13.How Long Should I Take Lamisil?
14.Can Lamisil Cause Allergic Reactions?
15.Is Lamisil Safe for Pregnant Women?
16.Is Alcohol Consumption Safe While Taking Lamisil?
17.Can Lamisil Affect Birth Control Pills?
18.Can Lamisil Be Used Topically on Nails?
19.What Precautions Should I Take While Using Lamisil?
20.Is Lamisil Effective Against Candida Infections?
21.Can Lamisil Cause Photosensitivity?
22.Is Lamisil Safe for Breastfeeding Mothers?
23.Can Lamisil Be Used for Jock Itch?
24.Is Lamisil Available Over-the-Counter?
25.Can Lamisil Be Used for Thrush?
26.Can Lamisil Be Used for Tinea Versicolor?
27.Is Lamisil Safe for Individuals with Liver Disease?
28.Can Lamisil Cause Gastrointestinal Distress?
29.Can Lamisil Be Used in Conjunction with Other Antifungal Medications?
30.How Often Should I Apply Lamisil Cream for Topical Use?
📚 Sources Used for FAQ Content:
Information on terbinafine (the active ingredient in Lamisil) is drawn from regulatory approvals across major markets, dermatology and infectious disease treatment guidelines, podiatric medical literature on onychomycosis management, and clinical experience accumulated since the medication's approval in the early 1990s. Lamisil was developed by Sandoz Pharmaceuticals (which became Novartis after the 1996 merger with Ciba-Geigy) and remains a market-leading brand for dermatophyte infections worldwide.- U.S. FDA - Lamisil oral tablets approved 1996 for onychomycosis
- European Medicines Agency (EMA) - Approved across EU member states
- UK MHRA - Regulatory authority for UK market
- Health Canada, Australia TGA, Japan PMDA - Major global regulators
- Swissmedic - Swiss regulatory authority (Lamisil's country of origin)
- WHO Essential Medicines List - Listed for dermatophyte infections
- Novartis (originally Sandoz) - Original developer and brand holder
- American Academy of Dermatology guidelines - U.S. dermatophyte management
- British Association of Dermatologists guidelines - UK standards
- American Podiatric Medical Association resources - Onychomycosis treatment
- European dermatology guidelines - Standards for tinea management
- CDC fungal disease guidance - U.S. recommendations
- Pediatric dermatology guidelines - Terbinafine in children (approved age 4+)
- Pivotal Phase III trials - Established efficacy for onychomycosis
- Cochrane systematic reviews - Meta-analyses comparing terbinafine to griseofulvin and azoles
- Head-to-head trials - Terbinafine vs itraconazole, terbinafine vs griseofulvin
- Pediatric tinea capitis studies - Particularly for Trichophyton species
- UpToDate, DynaMed, BNF - Clinical decision support databases
- FDA FAERS, EMA EudraVigilance, MHRA Yellow Card - Post-marketing surveillance for hepatotoxicity and other rare effects
- Liver injury database (LiverTox) - NIH-maintained drug-induced liver injury resource
Note: brand Lamisil and generic terbinafine products are bioequivalent. Clinical evidence applies to all terbinafine products.
FAQ Reviewed and Referenced By:
The Medication Guide content for Lamisil reflects published research and clinical guidance from internationally recognised authorities in dermatology and podiatric medicine. The Lamisil-specific panel includes podiatric specialists alongside dermatologists, reflecting that onychomycosis - Lamisil's primary indication - is commonly managed by both specialties. All listed experts have substantial peer-reviewed publication records.
Roxborough Memorial Hospital - Philadelphia, USA
Consultant in lower extremity infectious diseases and Fellow of the Infectious Diseases Society of America. One of the foremost podiatric authorities on onychomycosis treatment. Extensive publications on terbinafine clinical use, lower extremity infection management, and antifungal therapy.
Temple University School of Podiatric Medicine - Philadelphia, USA
Clinical Professor at Temple University, podiatric dermatology specialist. Author and co-editor of multiple textbooks on podiatric dermatology and lower extremity skin conditions. Active researcher on onychomycosis treatment outcomes and patient adherence.
JDD Therapeutics, Touro University Nevada - Henderson, USA
Research Director, Las Vegas-based dermatology research center. Editor-in-chief of the Journal of Clinical and Aesthetic Dermatology. Extensive publications on cutaneous antifungal therapy, acne, rosacea, and dermatologic pharmacology. Major contributor to clinical dermatology continuing education.
Wake Forest University School of Medicine - Winston-Salem, USA
Professor of Dermatology, Pathology and Social Sciences. Internationally recognised clinical researcher on dermatology drug therapy, patient adherence, and treatment outcomes. Author of more than 1,000 peer-reviewed publications. Founder of the National Psoriasis Foundation Medical Board.
Tulane University School of Medicine - New Orleans, USA
Joseph Chastain Professor and Chair of Dermatology at Tulane. Past President of the Women's Dermatologic Society. Extensive clinical and research experience in dermatologic infections, cutaneous medicine, and clinical dermatology education.
Note: this panel reflects published evidence and guidance from the listed authorities; it does not imply individual endorsement of this specific medication guide.
More Anti-Fungal Medications
